AstraZeneca PLC (NASDAQ:AZN) Q4 2024 Earnings Call Transcript February 6, 2025 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.05 EPS, expectations were $1.07. Pascal Soriot ...

Parnassus Growth Equity Fund stated the following regarding AstraZeneca PLC (NASDAQ:AZN) in its Q4 2024 investor letter: “We sold two Health Care positions during the quarter, pharmaceutical ...

AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why AZN stock is a Buy.

AstraZeneca PLC (NASDAQ:AZN) is facing ongoing investigations in China regarding suspected unpaid importation taxes, which could result in significant fines. The company experienced a 3% decline in Q4 ...

Second, thanks to the progress of our collaboration with AstraZeneca. Up to year-end 2024, $47 million have been paid to Cellectis under the joint research and collaboration agreement of which $25 ...

Cellectis demonstrated robust performance in Q4 2024, significantly outperforming market expectations. The company’s strategic initiatives, including its partnership with AstraZeneca ...

Revenue: $1.5 million for Q4 2024; $27.9 million for the full year ... targeting a less competitive landscape. AstraZeneca's initiation of seven Phase 3 trials with rilvegostomig, derived from ...